## Hepatology Admission [613]

Common Present on Admission Diagnosis	
] Acidosis	Details
Acute Post-Hemorrhagic Anemia	Details
] Acute Renal Failure	Details
] Acute Respiratory Failure	Details
Acute Thromboembolism of Deep Veins of Lower Extremities	Details
] Anemia	Details
] Bacteremia	Details
] Bipolar disorder, unspecified	Details
Cardiac Arrest	Details
] Cardiac Dysrhythmia	Details
] Cardiogenic Shock	Details
] Decubitus Ulcer	Details
Dementia in Conditions Classified Elsewhere	Details
] Disorder of Liver	Details
] Electrolyte and Fluid Disorder	Details
Intestinal Infection due to Clostridium Difficile	Details
Methicillin Resistant Staphylococcus Aureus Infection	Details
Obstructive Chronic Bronchitis with Exacerbation	Details
Other Alteration of Consciousness	Details
Other and Unspecified Coagulation Defects	Details
Other Pulmonary Embolism and Infarction	Details
Phlebitis and Thrombophlebitis	Details
Protein-calorie Malnutrition	Details
Psychosis, unspecified psychosis type	Details
Schizophrenia Disorder	Details
] Sepsis	Details
Septic Shock	Details
] Septicemia	Details
Type II or Unspecified Type Diabetes Mellitus with Mention of Complication, Not Stated as Uncontrolled	Details
Urinary Tract Infection, Site Not Specified	Details
dmission or Observation (Single Response)	
) Admit to Inpatient	Diagnosis:
	Admitting Physician:
	Level of Care: Patient Condition:
	Bed request comments:
	Certification: I certify that based on my best clinical judgme
	and the patient's condition as documented in the HP and
	progress notes, I expect that the patient will need hospital
	services for two or more midnights.
) Outpatient observation services under general	Diagnosis:
supervision	Admitting Physician:
•	Patient Condition:
	Bed request comments:
) Outpatient in a bed - extended recovery	Diagnosis:
•	Admitting Physician:
	Bed request comments:

( ) Admit to Inpatient	Diagnosis: Admitting Physician:
	Level of Care:
	Patient Condition:
	Bed request comments:
	Certification: I certify that based on my best clinical judgment
	and the patient's condition as documented in the HP and
	progress notes, I expect that the patient will need hospital
	services for two or more midnights.
( ) Outpatient observation services under general	Diagnosis:
supervision	Admitting Physician:
	Patient Condition:
() O had's al's a had sales deduces	Bed request comments:
() Outpatient in a bed - extended recovery	Diagnosis:
	Admitting Physician: Bed request comments:
Admission (Single Response) Patient has active status order on file.	
r allow has asing states order on me.	
( ) Admit to inpatient	Diagnosis:
	Admitting Physician:
	Level of Care:
	Patient Condition:
	Bed request comments:
	Certification: I certify that based on my best clinical judgmen and the patient's condition as documented in the HP and
	progress notes, I expect that the patient will need hospital
	services for two or more midnights.
	services for two or more midnights.
Code Status	
] Full code	Code Status decision reached by:
] DNR	
DNR (Do Not Resuscitate)	Does patient have decision-making capacity?
[] Consult to Palliative Care Service	Priority:
	Reason for Consult?
	Order?
	Name of referring provider: Enter call back number:
[] Consult to Social Work	Reason for Consult:
Modified Code	Does patient have decision-making capacity?
J Wodined Code	Modified Code restrictions:
1 Treatment Restrictions	Treatment Restriction decision reached by:
1 Treatment resultations	Specify Treatment Restrictions:
solation	
] Airborne isolation status	Details
Contact isolation status	Details
Droplet isolation status	Details
Enteric isolation status	Details
Precautions	
Aspiration precautions	Details
[] Fall precautions	Increased observation level needed:
Latex precautions	Details
] Seizure precautions	Increased observation level needed:
Nursing	
Vital Signs	
[] Vital signs - Per Unit Protocol	Routine, Per unit protocol
Printed on 4/18/2019 at 2:06 PM from SLIP	Page 2 of

[] Vital signs-Q4H	Routine, Every 4 hours For Until specified
Telemetry Order	
[] Telemetry	"And" Linked Panel
[] Telemetry monitoring	Routine, Continuous Order: Place in Centralized Telemetry Monitor: EKG Monitoring Only (Telemetry Box) Reason for telemetry: Chest pain syndrome Can be off of Telemetry for tests and baths? Yes
[] Telemetry Additional Setup Information	Routine, Continuous High Heart Rate (BPM): 120 Low Heart Rate(BPM): 50 High PVC's (per minute): 10 High SBP(mmHg): 175 Low SBP(mmHg): 100 High DBP(mmHg): 95 Low DBP(mmHg): 40 Low Mean BP: 60 High Mean BP: 120 Low SPO2(%): 94
Activity	
[] Strict bed rest	Routine, Until discontinued, Starting S
[] Bed rest with bathroom privileges	Routine, Until discontinued, Starting S Bathroom Privileges: with bathroom privileges
[] Ambulate with assistance	Routine, 3 times daily Specify: with assistance
[] Activity as tolerated	Routine, Until discontinued, Starting S Specify: Activity as tolerated
Nursing	
[X] Head of bed 30 degrees	Routine, Until discontinued, Starting S Head of bed: 30 degrees
[X] Daily weights	Routine, Daily
[X] Intake and Output	Routine, Every 8 hours Including bowel movements
[] Bedside glucose - every 4 hours	Routine, Every 4 hours
Bedside glucose - AC & HS  Nasogastric Tube Orders	Routine, 4 times daily before meals and at bedtime
[] Nasogastric tube insertion	Routine, Once Type:
[] Nasogastric tube maintenance	Routine, Until discontinued, Starting S Tube Care Orders:
[] Insert and Maintain Foley	
[] Insert Foley catheter	Routine, Once Type: Size: Urinometer needed:
[] Foley Catheter Care	Routine, Until discontinued, Starting S Orders: Maintain
[] Change foley catheter	Routine, Once
[] Oral care	Routine, Every 8 hours
Notify	
[X] Notify Physician (Specify)	Routine, Until discontinued, Starting S, Active bleeding
[X] Notify Physician (Specify)	Routine, Until discontinued, Starting S, Change in condition or Glasgow Coma Score less than 13

[X] Notify Physician(vitals,output,pulse ox)	Routine, Until discontinued, Starting S Temperature greater than: 101.5 Temperature less than: Systolic BP greater than: 160 Systolic BP less than: 80 Diastolic BP greater than: Diastolic BP less than: Heart rate greater than (BPM): 110 Heart rate less than (BPM): 50 Respiratory rate greater than: 30 Respiratory rate less than: 10 SpO2 less than: Urine Output less than: 30ml/hr or less than 250ml/8 hours Output (Specify) greater than: Other:
Diet	
NPO-Except ice chips	Diet effective now, Starting S NPO: Pre-Operative fasting options: Diet effective now, Starting S
	NPO: Except Ice chips Pre-Operative fasting options:
[] Diet-500ml fluid restriction	Diet effective now, Starting S Diet(s): Advance Diet as Tolerated? Liquid Consistency: Fluid Restriction: Fluid Restriction 500 ml Foods to Avoid:
[] Diet-1000ml fluid restriction	Diet effective now, Starting S Diet(s): Advance Diet as Tolerated? Liquid Consistency: Fluid Restriction: Fluid Restriction 1000 ml Foods to Avoid:
[] Diet-2gm Sodium	Diet effective now, Starting S Diet(s): 2 GM Potassium Advance Diet as Tolerated? Liquid Consistency: Fluid Restriction: Foods to Avoid:
[] Diet-1800 Carb Control Diabetic	Diet effective now, Starting S Diet(s): Other Diabetic/Cal Diabetic/Calorie: 1800 Kcal/202 gm Carbohydrate Advance Diet as Tolerated? Liquid Consistency: Fluid Restriction: Foods to Avoid:
[] Diet-Renal(80GM, 2-3GM Na, 2-3GM K)	Diet effective now, Starting S Diet(s): Renal (80GM Pro, 2-3GM Na, 2-3GM K) Advance Diet as Tolerated? Liquid Consistency: Fluid Restriction: Foods to Avoid:
[] Diet-Clear liquids	Diet effective now, Starting S Diet(s): Clear Liquids Advance Diet as Tolerated? Liquid Consistency: Fluid Restriction: Foods to Avoid:

[] Diet-Full liquids	Diet effective now, Starting S Diet(s): Full Liquids Advance Diet as Tolerated? Liquid Consistency: Fluid Restriction: Foods to Avoid:
IV Fluids	
Peripheral IV Access	
[X] Initiate and maintain IV	
[X] Insert peripheral IV	Routine, Once
[X] sodium chloride 0.9 % flush	10 mL, intravenous, every 12 hours scheduled
[X] sodium chloride 0.9 % flush	10 mL, intravenous, PRN, line care
IV Fluid	
[] sodium chloride 0.45 % infusion 1000 mL	intravenous, at 75 mL/hr, continuous
[] sodium chloride 0.45 % with potassium chloride 20 mEg/L infusion	75 mL/hr, intravenous, continuous
[] dextrose 5%-0.45% sodium chloride 1,000 mL infusion	75 mL/hr, intravenous, continuous
Medications	
Pharmacy Consults	
[X] Pharmacy consult to manage dosing of medication	Routine, Until discontinued, Starting S Adjust dose for: renal function
Medications	
[] zinc sulfate (ZINCATE) capsule	220 mg, oral, daily
[] magnesium oxide tablet	400 mg, oral, 3 times daily
[] magnesium sulfate 2 g in sodium chloride 0.45 % 0.45 % 100 mL IVPB	2 g, intravenous, for 1 Hours, once, For 1 Doses
[] octreotide (SANDOSTATIN) IV Bolus Once AND Maintenance 25 mcg/hr	"And" Linked Panel
[] octreotide (SANDOSTATIN) bolus injection	100 mcg, intravenous, once, For 1 Doses Bolus once initial dose. Infusion to start immediately after bolus. May cause Q-T interval prolongation.
[] octreotide (SandoSTATIN) maintenance infusion	25 mcg/hr, intravenous, for 40 Hours, continuous May cause Q-T interval prolongation
[] octreotide (SANDOSTATIN) IV Bolus Once AND Maintenance 50 mcg/hr	"And" Linked Panel
[] octreotide (SANDOSTATIN) bolus injection	100 mcg, intravenous, once, For 1 Doses Bolus once initial dose. Infusion to start immediately after bolus. May cause Q-T interval prolongation.
[] octreotide (SandoSTATIN) maintenance infusion	50 mcg/hr, intravenous, continuous May cause Q-T interval prolongation
pantoprazole (PROTONIX) IV or ORAL	"Or" Linked Panel
pantoprazole (PROTONIX) IV or ORAL pantoprazole (PROTONIX) EC tablet	
	40 mg, oral, daily at 0600
<ul><li>[] pantoprazole (PROTONIX) EC tablet</li><li>[] pantoprazole (PROTONIX) 40 mg in sodium chloride 0.9</li></ul>	40 mg, oral, daily at 0600 Indication(s) for Proton Pump Inhibitor (PPI) Therapy: 40 mg, intravenous, daily at 0600
<ul><li>[] pantoprazole (PROTONIX) EC tablet</li><li>[] pantoprazole (PROTONIX) 40 mg in sodium chloride 0.9 % 10 mL injection</li></ul>	40 mg, oral, daily at 0600 Indication(s) for Proton Pump Inhibitor (PPI) Therapy:
<ul><li>[] pantoprazole (PROTONIX) EC tablet</li><li>[] pantoprazole (PROTONIX) 40 mg in sodium chloride 0.9 % 10 mL injection</li></ul> Ascites	40 mg, oral, daily at 0600 Indication(s) for Proton Pump Inhibitor (PPI) Therapy: 40 mg, intravenous, daily at 0600 Indication(s) for Proton Pump Inhibitor (PPI) Therapy:
[] pantoprazole (PROTONIX) EC tablet  [] pantoprazole (PROTONIX) 40 mg in sodium chloride 0.9 % 10 mL injection  Ascites  [] furosemide (LASIX) injection	40 mg, oral, daily at 0600 Indication(s) for Proton Pump Inhibitor (PPI) Therapy: 40 mg, intravenous, daily at 0600 Indication(s) for Proton Pump Inhibitor (PPI) Therapy: 40 mg, intravenous, 2 times daily at 0900, 1700
[] pantoprazole (PROTONIX) EC tablet  [] pantoprazole (PROTONIX) 40 mg in sodium chloride 0.9 % 10 mL injection  Ascites  [] furosemide (LASIX) injection [] furosemide (LASIX) tablet	40 mg, oral, daily at 0600 Indication(s) for Proton Pump Inhibitor (PPI) Therapy: 40 mg, intravenous, daily at 0600 Indication(s) for Proton Pump Inhibitor (PPI) Therapy:  40 mg, intravenous, 2 times daily at 0900, 1700  40 mg, oral, 2 times daily at 0900, 1700
[] pantoprazole (PROTONIX) EC tablet  [] pantoprazole (PROTONIX) 40 mg in sodium chloride 0.9 % 10 mL injection  Ascites  [] furosemide (LASIX) injection [] furosemide (LASIX) tablet	40 mg, oral, daily at 0600 Indication(s) for Proton Pump Inhibitor (PPI) Therapy: 40 mg, intravenous, daily at 0600 Indication(s) for Proton Pump Inhibitor (PPI) Therapy:  40 mg, intravenous, 2 times daily at 0900, 1700 40 mg, oral, 2 times daily at 0900, 1700 100 mg, oral, daily
[] pantoprazole (PROTONIX) 40 mg in sodium chloride 0.9 % 10 mL injection  Ascites [] furosemide (LASIX) injection [] furosemide (LASIX) tablet	40 mg, oral, daily at 0600 Indication(s) for Proton Pump Inhibitor (PPI) Therapy: 40 mg, intravenous, daily at 0600 Indication(s) for Proton Pump Inhibitor (PPI) Therapy:  40 mg, intravenous, 2 times daily at 0900, 1700 40 mg, oral, 2 times daily at 0900, 1700 100 mg, oral, daily MONITOR POTASSIUM LEVELS. AVOID SALT
[] pantoprazole (PROTONIX) EC tablet  [] pantoprazole (PROTONIX) 40 mg in sodium chloride 0.9 % 10 mL injection  Ascites  [] furosemide (LASIX) injection [] furosemide (LASIX) tablet	40 mg, oral, daily at 0600 Indication(s) for Proton Pump Inhibitor (PPI) Therapy: 40 mg, intravenous, daily at 0600 Indication(s) for Proton Pump Inhibitor (PPI) Therapy:  40 mg, intravenous, 2 times daily at 0900, 1700 40 mg, oral, 2 times daily at 0900, 1700 100 mg, oral, daily

[X] acetaminophen (TYLENOL) tablet OR oral solution	"Or" Linked Panel sources. (Cirrhosis patients maximum: 2 grams per day from all
PRN Mild Pain (Pain score 1-3) (adjust dose for renal/liver function and age)	
[] phytonadione (AQUA-MEPHYTON) injection	10 mg, subcutaneous, daily, For 3 Days
[] carvedilol (COREG) tablet	6.25 mg, oral, 2 times daily at 0600, 1800 HOLD parameters for this order: Contact Physician if:
[] propranolol (INDERAL) tablet	20 mg, oral, 2 times daily at 0600, 1800 HOLD parameters for this order: Contact Physician if:
Variceal Bleeding / Portal HTN	
[] rifaximin (XIFAXAN) tablet	550 mg, oral, 2 times daily Indication:
[] neomycin (MYCIFRADIN) tablet	1,000 mg, oral, 3 times daily Reason for Therapy:
[] lactulose solution (Enema)	START AFTER FIRST BOWEL MOVEMENT. HOLD FOR MORE THAN 5 BOWEL MOVEMENTS IN 24 HOURS.  200 g, rectal, once, For 1 Doses
[ ] lactulose (CHRONULAC) 10 gram/15 mL solution [ ] lactulose (CHRONULAC) 10 gram/15 mL solution	10 g, oral, every 1 hour STOP AFTER FIRST BOWEL MOVEMENT AND START 3 TIMES DAILY DOSING. 10 g, oral, 3 times daily
Encephalopathy	
[] albumin human 25 % bottle	50 mL, intravenous, at 50 mL/hr, once, For 1 Doses Indication:
[] vancomycin (VANCOCIN) IV	intravenous, every 24 hours Reason for Therapy:
[] piperacillin-tazobactam (ZOSYN) IV	3.375 g, intravenous, every 8 hours Reason for Therapy:
[] levofloxacin (LEVAQUIN) IV	500 mg, intravenous, every 24 hours Reason for Therapy:
[] ceftriaxone (ROCEPHIN) IV	1 g, intravenous, for 30 Minutes, every 24 hours Reason for Therapy:
Spont. Bacterial Peritonitis	maication.
[] albumin human 5 % bottle	25 g, intravenous, at 250 mL/hr, for 120 Minutes, every 4 hours, For 2 Doses Indication:
[] albumin human 5 % bottle	12.5 g, intravenous, at 125 mL/hr, for 120 Minutes, every 4 hours, For 2 Doses Indication:
[] albumin human 25 % bottle	50 mL, intravenous, at 50 mL/hr, for 60 Minutes, every 8 hou Indication:
octreotide (SANDOSTATIN) injection	10 mg, oral, 3 times daily at 0900, 1300, 1700 100 mcg, subcutaneous, every 8 hours
Hepatorenal Syndrome      midodrine (PROAMATINE) tablet	10 mg aval 2 times daily at 0000 1200 1700
	Indication:
[] albumin human 25 % bottle	50 mL, intravenous, at 50 mL/hr, for 60 Minutes, once, For 1 Doses

<u></u>	
[X] acetaminophen (TYLENOL) tablet	650 mg, oral, every 6 hours PRN, mild pain (score 1-3) Maximum of 3 grams of acetaminophen per day from all sources. Give the tablet if the patient can tolerate oral medication. (Cirrhosis patients maximum: 2 grams per day from all sources)
[X] acetaminophen (TYLENOL)suspension	650 mg, oral, every 6 hours PRN, mild pain (score 1-3) Maximum of 3 grams of acetaminophen per day from all sources. (Cirrhosis patients maximum: 2 grams per day from all sources). Use if patient cannot tolerate oral tablet.
Antiemetics	
[X] ondansetron (ZOFRAN) IV or Oral	"Or" Linked Panel
[X] ondansetron ODT (ZOFRAN-ODT) disintegrating tablet	4 mg, oral, every 8 hours PRN, nausea, vomiting Give if patient is able to tolerate oral medication.
[X] ondansetron (ZOFRAN) 4 mg/2 mL injection	4 mg, intravenous, every 8 hours PRN, nausea, vomiting Give if patient is UNable to tolerate oral medication OR if a faster onset of action is required.
[X] promethazine (PHENERGAN) IV or Oral or Rectal	"Or" Linked Panel
[X] promethazine (PHENERGAN) 12.5 mg IV	12.5 mg, intravenous, every 6 hours PRN, nausea, vomiting Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral or rectal medication OR if a faster onset of action is required.
[X] promethazine (PHENERGAN) tablet	12.5 mg, oral, every 6 hours PRN, nausea, vomiting Give if ondansetron (ZOFRAN) is ineffective and patient is able to tolerate oral medication.
[X] promethazine (PHENERGAN) suppository	12.5 mg, rectal, every 6 hours PRN, nausea, vomiting Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral medication.
Antiemetics	
[X] ondansetron (ZOFRAN) IV or Oral	"Or" Linked Panel
[X] ondansetron ODT (ZOFRAN-ODT) disintegrating tablet	4 mg, oral, every 8 hours PRN, nausea, vomiting Give if patient is able to tolerate oral medication.
[X] ondansetron (ZOFRAN) 4 mg/2 mL injection	4 mg, intravenous, every 8 hours PRN, nausea, vomiting Give if patient is UNable to tolerate oral medication OR if a faster onset of action is required.
[] promethazine (PHENERGAN) IV or Oral or Rectal	"Or" Linked Panel
[] promethazine (PHENERGAN) 12.5 mg in sodium chloride 0.9 % 0.9 % 20 mL for Alaris pump syringe option	12.5 mg, intravenous, every 6 hours PRN, nausea, vomiting Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral or rectal medication OR if a faster onset of action is required.
[] promethazine (PHENERGAN) tablet	12.5 mg, oral, every 6 hours PRN, nausea, vomiting Give if ondansetron (ZOFRAN) is ineffective and patient is able to tolerate oral medication.
[] promethazine (PHENERGAN) suppository	12.5 mg, rectal, every 6 hours PRN, nausea, vomiting Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral medication.
Antiemetics	
[X] ondansetron (ZOFRAN) IV or Oral	"Or" Linked Panel
[X] ondansetron ODT (ZOFRAN-ODT) disintegrating tablet	4 mg, oral, every 8 hours PRN, nausea, vomiting Give if patient is able to tolerate oral medication.
[X] ondansetron (ZOFRAN) 4 mg/2 mL injection	4 mg, intravenous, every 8 hours PRN, nausea, vomiting Give if patient is UNable to tolerate oral medication OR if a faster onset of action is required.
[] promethazine (PHENERGAN) IVPB or Oral or Rectal	"Or" Linked Panel
[] promethazine (PHENERGAN) 25 mg in sodium chloride 0.9 % 50 mL IVPB	12.5 mg, intravenous, for 30 Minutes, every 6 hours PRN, nausea, vomiting Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral or rectal medication OR if a faster onset of action is required.

[] promethazine (PHENERGAN) tablet	12.5 mg, oral, every 6 hours PRN, nausea, vomiting Give if ondansetron (ZOFRAN) is ineffective and patient is able to tolerate oral medication.	
[] promethazine (PHENERGAN) suppository	12.5 mg, rectal, every 6 hours PRN, nausea, vomiting Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral medication.	
Insomnia: For Patients GREATER than or EQUAL to 70	years old (Single Response)	
() ramelteon (ROZEREM) tablet	8 mg, oral, nightly PRN, sleep	
Insomnia: For Patients LESS than 70 years old (Single Response)		
( ) zolpidem (AMBIEN) tablet	5 mg, oral, nightly PRN, sleep	
( ) ramelteon (ROZEREM) tablet	8 mg, oral, nightly PRN, sleep	

## VTE

**DVT Risk and Prophylaxis Tool (Single Response)** 

Low Risk Definition Moderate Risk Definition

Pharmacologic prophylaxis must be addressed. Mechanical prophylaxis is optional unless pharmacologic is contraindicated. High Risk Definition

Both pharmacologic AND mechanical prophylaxis must be addressed.

Age less than 60 years and NO other VTE risk factors One or more of the following medical conditions: One or more of the following medical conditions:

Patient already adequately anticoagulated CHF, MI, lung disease, pneumonia, active inflammation, dehydration, varicose veins, cancer, sepsis, obesity, previous stroke, rheumatologic disease, sickle cell disease, leg swelling, ulcers, venous stasis and nephrotic syndrome Thrombophilia (Factor V Leiden, prothrombin variant mutations, anticardiolipin antibody syndrome; antithrombin, protein C or protein S deficiency; hyperhomocysteinemia; myeloproliferative disorders)

Age 60 and above Severe fracture of hip, pelvis or leg

Central line Acute spinal cord injury with paresis

History of DVT or family history of VTE Multiple major traumas

Anticipated length of stay GREATER than 48 hours Abdominal or pelvic surgery for CANCER

Less than fully and independently ambulatory Acute ischemic stroke

Estrogen therapy History of PE

Moderate or major surgery (not for cancer)

Major surgery within 3 months of admission

( ) Low Risk of DVT	
[] Low Risk (Single Response)	
() Low risk of VTE	Routine, Once
	Low risk: Due to low risk, no VTE prophylaxis is needed.
	Will encourgae early ambulation
() Moderate Risk of DVT - Surgical	
Address pharmacologic prophylaxis by selecting one of the foll pharmacologic prophylaxis is contraindicated.	owing. Mechanical prophylaxis is optional unless
[] Moderate Risk	
[] Moderate risk of VTE	Routine, Once
[] Moderate Risk Pharmacological Prophylaxis - Surgical Patient (Single Response)	
() Patient is currently receiving therapeutic anticoagulation	Routine, Once
	No pharmacologic VTE prophylaxis because: patient is
	already on therapeutic anticoagulation for other indication.
() 0	Therapy for the following:
() Contraindications exist for pharmacologic prophylaxis	Routine, Once
	No pharmacologic VTE prophylaxis due to the following contraindication(s):
() enoxaparin (LOVENOX) injection (Single Response)	
() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1

()	enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1
	. (10)(5)(0)()	For Patients with CrCL LESS than 30 mL/min
()	1 \ / 3 \ 3	30 mg, subcutaneous, 2 times daily at 0600, 1800 (time
	between 100-139 kg and CrCl GREATER than 30	critical), Starting S+1
	mL/min	For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
()	enoxaparin (LOVENOX) syringe - For Patients weight	40 mg, subcutaneous, 2 times daily at 0600, 1800 (time
	140 kg or GREATER and CrCl GREATER than 30	critical), Starting S+1
	mL/min	For Patient weight of 140 kg or GREATER and CrCl GREATER than 30 mL/min
()	fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, Starting S+1
		If the patient does not have a history of or suspected case
		of Heparin-Induced Thrombocytopenia (HIT) do NOT order
		this medication. Contraindicated in patients LESS than
		50kg, prior to surgery/invasive procedure, or CrCl LESS
		than 30 mL/min.
		This patient has a history of or suspected case of
		Heparin-Induced Thrombocytopenia (HIT):
()	heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM
	heparin (porcine) injection (Recommended for patients	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00
	with high risk of bleeding, e.g. weight < 50kg and age >	AM
	75yrs)	Recommended for patients with high risk of bleeding, e.g.
		weight LESS than 50kg and age GREATER than 75yrs.
()	warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical), Starting S+1
		Indication:
()	Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S
		Indication:
[] N	Mechanical Prophylaxis (Single Response)	
()	Contraindications exist for mechanical prophylaxis	Routine, Once
		No mechanical VTE prophylaxis due to the following
		contraindication(s):
· · ·	Place/Maintain sequential compression device continuous	Routine, Continuous
	Place sequential compression device and antiembolic stockings	"And" Linked Panel
	Place/Maintain sequential compression device	Routine, Continuous
	continuous	·
[]	Place antiembolic stockings	Routine, Once
() Mod	derate Risk of DVT - Non-Surgical	
	lress pharmacologic prophylaxis by selecting one of the follormacologic prophylaxis is contraindicated.	owing. Mechanical prophylaxis is optional unless
[] N	Moderate Risk	
[]	Moderate risk of VTE	Routine, Once
	Noderate Risk Pharmacological Prophylaxis - Ion-Surgical Patient (Single Response)	
	Patient is currently receiving therapeutic anticoagulation	Routine, Once
`′	, , , , , , , , , , , , , , , , , , , ,	No pharmacologic VTE prophylaxis because: patient is
		already on therapeutic anticoagulation for other indication.
		Therapy for the following:
()	Contraindications exist for pharmacologic prophylaxis	Routine, Once
		No pharmacologic VTE prophylaxis due to the following contraindication(s):
()	enoxaparin (LOVENOX) injection (Single Response)	22
\ \\	enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 1700 (time critical), Starting
		S
()	enoxaparin (LOVENOX) syringe - For Patients with CrCL	30 mg, subcutaneous, daily at 1700 (time critical), Starting
	LESS than 30 mL/min	S
		For Patients with CrCL LESS than 30 mL/min

() enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min	30 mg, subcutaneous, 2 times daily, Starting S For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
<ul> <li>enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min</li> </ul>	40 mg, subcutaneous, 2 times daily, Starting S For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT), do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours
() heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	5,000 Units, subcutaneous, every 12 hours Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
( ) warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical) Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
[ ] Mechanical Prophylaxis (Single Response)	
() Contraindications exist for mechanical prophylaxis	Routine, Once  No mechanical VTE prophylaxis due to the following contraindication(s):
( ) Place/Maintain sequential compression device continuous	Routine, Continuous
( ) Place sequential compression device and antiembolic stockings	"And" Linked Panel
[] Place/Maintain sequential compression device continuous	Routine, Continuous
[] Place antiembolic stockings	Routine, Once
) High Risk of DVT - Surgical	
Address both pharmacologic and mechanical prophylaxis by or	dering from Pharmacological and Mechanical Prophylaxis.
[] High Risk	
[] High risk of VTE	Routine, Once
[] High Risk Pharmacological Prophylaxis - Surgical Patient (Single Response)	
() Patient is currently receiving therapeutic anticoagulation	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following:
() Contraindications exist for pharmacologic prophylaxis	Routine, Once  No pharmacologic VTE prophylaxis due to the following contraindication(s):
( ) enoxaparin (LOVENOX) injection (Single Response)	
( ) enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1
() enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 For Patients with CrCL LESS than 30 mL/min
() enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min	30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
() enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min	40 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min

()	fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min.  This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
()	heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM
()	heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
()	warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical), Starting S+1 Indication:
()	Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
[]	Mechanical Prophylaxis (Single Response)	
()	Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s):
()	Place/Maintain sequential compression device continuous	Routine, Continuous
()	Place sequential compression device and antiembolic stockings	"And" Linked Panel
[]	Place/Maintain sequential compression device continuous	Routine, Continuous
$\overline{[}$	Place antiembolic stockings	Routine, Once
() Hig	gh Risk of DVT - Non-Surgical	
Ad	dress both pharmacologic and mechanical prophylaxis by or	dering from Pharmacological and Mechanical Prophylaxis.
Ι <u>Ι</u>	High Risk	
	High risk of VTE	Routine, Once
	High Risk Pharmacological Prophylaxis - Non-Surgical Patient (Single Response)	
()	Patient is currently receiving therapeutic anticoagulation	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following:
()	Contraindications exist for pharmacologic prophylaxis	Routine, Once  No pharmacologic VTE prophylaxis due to the following contraindication(s):
( )	enoxaparin (LOVENOX) injection (Single Response)	
(	) enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 1700 (time critical), Starting S
(	) enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 1700 (time critical), Starting S For Patients with CrCL LESS than 30 mL/min
(	<ul> <li>enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min</li> </ul>	30 mg, subcutaneous, 2 times daily, Starting S For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
(	) enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min	40 mg, subcutaneous, 2 times daily, Starting S For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min

()		
( )	fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
()	heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours
()	heparin (porcine) injection (Recommended for patients	5,000 Units, subcutaneous, every 12 hours
()		
	with high risk of bleeding, e.g. weight < 50kg and age >	Recommended for patients with high risk of bleeding, e.g.
	75yrs)	weight LESS than 50kg and age GREATER than 75yrs.
( )	warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical)
		Indication:
()	Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S
		Indication:
[] [	Mechanical Prophylaxis (Single Response)	
()	Contraindications exist for mechanical prophylaxis	Routine, Once
( )		No mechanical VTE prophylaxis due to the following
		contraindication(s):
()	Place/Maintain sequential compression device	Routine, Continuous
( )	continuous	Houtine, Johtmadas
7)	Place sequential compression device and antiembolic	"And" Linked Panel
( )	·	Allu Lilikeu Fallei
<u>- 1</u>	stockings	Davidina Cantinuava
[]	·	Routine, Continuous
-	continuous	
	<u> </u>	Routine, Once
	h Risk of DVT - Surgical (Hip/Knee) dress both pharmacologic and mechanical prophylaxis by or	
	High risk of VTE	Routine, Once
	High Risk Pharmacological Prophylaxis - Hip or Knee	Routine, Once
	High Risk Pharmacological Prophylaxis - Hip or Knee (Arthroplasty) Surgical Patient (Single Response)	
	High Risk Pharmacological Prophylaxis - Hip or Knee	Routine, Once
	High Risk Pharmacological Prophylaxis - Hip or Knee (Arthroplasty) Surgical Patient (Single Response)	Routine, Once No pharmacologic VTE prophylaxis because: patient is
	High Risk Pharmacological Prophylaxis - Hip or Knee (Arthroplasty) Surgical Patient (Single Response)	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication.
	High Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following:
	High Risk Pharmacological Prophylaxis - Hip or Knee (Arthroplasty) Surgical Patient (Single Response)	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once
	High Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following
	High Risk Pharmacological Prophylaxis - Hip or Knee (Arthroplasty) Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation  Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
	High Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 2.5 mg, oral, every 12 hours, Starting S+1
()	High Risk Pharmacological Prophylaxis - Hip or Knee (Arthroplasty) Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation  Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
()	High Risk Pharmacological Prophylaxis - Hip or Knee (Arthroplasty) Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation  Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 2.5 mg, oral, every 12 hours, Starting S+1
()	High Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation  Contraindications exist for pharmacologic prophylaxis  apixaban (ELIQUIS) tablet  aspirin chewable tablet	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 2.5 mg, oral, every 12 hours, Starting S+1 Indications:
()	High Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation  Contraindications exist for pharmacologic prophylaxis  apixaban (ELIQUIS) tablet  aspirin chewable tablet aspirin (ECOTRIN) enteric coated tablet	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 2.5 mg, oral, every 12 hours, Starting S+1 Indications: 162 mg, oral, daily, Starting S+1
()	High Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation  Contraindications exist for pharmacologic prophylaxis  apixaban (ELIQUIS) tablet  aspirin chewable tablet aspirin (ECOTRIN) enteric coated tablet enoxaparin (LOVENOX) injection (Single Response)	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 2.5 mg, oral, every 12 hours, Starting S+1 Indications: 162 mg, oral, daily, Starting S+1 162 mg, oral, daily, Starting S+1
()	High Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation  Contraindications exist for pharmacologic prophylaxis  apixaban (ELIQUIS) tablet  aspirin chewable tablet aspirin (ECOTRIN) enteric coated tablet	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 2.5 mg, oral, every 12 hours, Starting S+1 Indications: 162 mg, oral, daily, Starting S+1 162 mg, oral, daily, Starting S+1 40 mg, subcutaneous, daily at 0600 (time critical), Starting
() () () () () ()	High Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation  Contraindications exist for pharmacologic prophylaxis  apixaban (ELIQUIS) tablet  aspirin chewable tablet aspirin (ECOTRIN) enteric coated tablet enoxaparin (LOVENOX) injection (Single Response) enoxaparin (LOVENOX) syringe - hip arthoplasty	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 2.5 mg, oral, every 12 hours, Starting S+1 Indications: 162 mg, oral, daily, Starting S+1 162 mg, oral, daily, Starting S+1 40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1
()	High Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation  Contraindications exist for pharmacologic prophylaxis  apixaban (ELIQUIS) tablet  aspirin chewable tablet aspirin (ECOTRIN) enteric coated tablet enoxaparin (LOVENOX) injection (Single Response) enoxaparin (LOVENOX) syringe - hip arthoplasty	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 2.5 mg, oral, every 12 hours, Starting S+1 Indications: 162 mg, oral, daily, Starting S+1 162 mg, oral, daily, Starting S+1 40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time
() () () () () ()	High Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation  Contraindications exist for pharmacologic prophylaxis  apixaban (ELIQUIS) tablet  aspirin chewable tablet aspirin (ECOTRIN) enteric coated tablet enoxaparin (LOVENOX) injection (Single Response) enoxaparin (LOVENOX) syringe - hip arthoplasty  enoxaparin (LOVENOX) syringe - knee arthroplasty	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 2.5 mg, oral, every 12 hours, Starting S+1 Indications: 162 mg, oral, daily, Starting S+1 162 mg, oral, daily, Starting S+1 40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1
() () () () () ()	High Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation  Contraindications exist for pharmacologic prophylaxis  apixaban (ELIQUIS) tablet  aspirin chewable tablet aspirin (ECOTRIN) enteric coated tablet enoxaparin (LOVENOX) injection (Single Response) enoxaparin (LOVENOX) syringe - hip arthoplasty  enoxaparin (LOVENOX) syringe - knee arthroplasty enoxaparin (LOVENOX) syringe - For Patients with CrCL	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 2.5 mg, oral, every 12 hours, Starting S+1 Indications: 162 mg, oral, daily, Starting S+1 162 mg, oral, daily, Starting S+1 40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1
() () () () () ()	High Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation  Contraindications exist for pharmacologic prophylaxis  apixaban (ELIQUIS) tablet  aspirin chewable tablet aspirin (ECOTRIN) enteric coated tablet enoxaparin (LOVENOX) injection (Single Response) enoxaparin (LOVENOX) syringe - hip arthoplasty  enoxaparin (LOVENOX) syringe - knee arthroplasty	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 2.5 mg, oral, every 12 hours, Starting S+1 Indications: 162 mg, oral, daily, Starting S+1 162 mg, oral, daily, Starting S+1 40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1
() () () () () () ()	High Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation  Contraindications exist for pharmacologic prophylaxis  apixaban (ELIQUIS) tablet  aspirin chewable tablet aspirin (ECOTRIN) enteric coated tablet enoxaparin (LOVENOX) injection (Single Response) enoxaparin (LOVENOX) syringe - hip arthoplasty  enoxaparin (LOVENOX) syringe - knee arthroplasty  enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min - knee/hip arthroplasty	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 2.5 mg, oral, every 12 hours, Starting S+1 Indications: 162 mg, oral, daily, Starting S+1 162 mg, oral, daily, Starting S+1 162 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 For Patients with CrCL LESS than 30 mL/min.
() () () () () ()	High Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation  Contraindications exist for pharmacologic prophylaxis  apixaban (ELIQUIS) tablet  aspirin chewable tablet aspirin (ECOTRIN) enteric coated tablet enoxaparin (LOVENOX) injection (Single Response) enoxaparin (LOVENOX) syringe - hip arthoplasty  enoxaparin (LOVENOX) syringe - knee arthroplasty  enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min - knee/hip arthroplasty	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 2.5 mg, oral, every 12 hours, Starting S+1 Indications: 162 mg, oral, daily, Starting S+1 162 mg, oral, daily, Starting S+1 162 mg, oral, daily, Starting S+1 30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients with CrCL LESS than 30 mL/min. 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time
() () () () () () ()	High Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation  Contraindications exist for pharmacologic prophylaxis  apixaban (ELIQUIS) tablet  aspirin chewable tablet aspirin (ECOTRIN) enteric coated tablet enoxaparin (LOVENOX) injection (Single Response) enoxaparin (LOVENOX) syringe - hip arthoplasty  enoxaparin (LOVENOX) syringe - knee arthroplasty  enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min - knee/hip arthroplasty  enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 2.5 mg, oral, every 12 hours, Starting S+1 Indications: 162 mg, oral, daily, Starting S+1 162 mg, oral, daily, Starting S+1 40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 For Patients with CrCL LESS than 30 mL/min. 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients with CrCL LESS than 30 mL/min.
	High Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation  Contraindications exist for pharmacologic prophylaxis  apixaban (ELIQUIS) tablet  aspirin chewable tablet aspirin (ECOTRIN) enteric coated tablet enoxaparin (LOVENOX) injection (Single Response) enoxaparin (LOVENOX) syringe - hip arthoplasty  enoxaparin (LOVENOX) syringe - knee arthroplasty  enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min - knee/hip arthroplasty	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 2.5 mg, oral, every 12 hours, Starting S+1 Indications: 162 mg, oral, daily, Starting S+1 162 mg, oral, daily, Starting S+1 40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 For Patients with CrCL LESS than 30 mL/min. 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight between 100-139 kg and CrCl
	High Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation  Contraindications exist for pharmacologic prophylaxis  apixaban (ELIQUIS) tablet  aspirin chewable tablet aspirin (ECOTRIN) enteric coated tablet enoxaparin (LOVENOX) injection (Single Response) enoxaparin (LOVENOX) syringe - hip arthoplasty  enoxaparin (LOVENOX) syringe - knee arthroplasty  enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min - knee/hip arthroplasty  enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 2.5 mg, oral, every 12 hours, Starting S+1 Indications: 162 mg, oral, daily, Starting S+1 162 mg, oral, daily, Starting S+1 40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 For Patients with CrCL LESS than 30 mL/min. 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Starting S+1
() () () () () () ()	High Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response)  Patient is currently receiving therapeutic anticoagulation  Contraindications exist for pharmacologic prophylaxis  apixaban (ELIQUIS) tablet  aspirin chewable tablet aspirin (ECOTRIN) enteric coated tablet enoxaparin (LOVENOX) injection (Single Response) enoxaparin (LOVENOX) syringe - hip arthoplasty  enoxaparin (LOVENOX) syringe - knee arthroplasty  enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min - knee/hip arthroplasty  enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 2.5 mg, oral, every 12 hours, Starting S+1 Indications: 162 mg, oral, daily, Starting S+1 162 mg, oral, daily, Starting S+1 162 mg, oral, daily, Starting S+1 30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients with CrCL LESS than 30 mL/min. 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients with CrCL LESS than 30 mL/min. 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min.
() () () () () () ()	High Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response)  Patient is currently receiving therapeutic anticoagulation  Contraindications exist for pharmacologic prophylaxis  apixaban (ELIQUIS) tablet  aspirin chewable tablet aspirin (ECOTRIN) enteric coated tablet enoxaparin (LOVENOX) injection (Single Response) enoxaparin (LOVENOX) syringe - hip arthoplasty  enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min - knee/hip arthroplasty  enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min  enoxaparin (LOVENOX) syringe - For Patients weight	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 2.5 mg, oral, every 12 hours, Starting S+1 Indications: 162 mg, oral, daily, Starting S+1 162 mg, oral, daily, Starting S+1 162 mg, oral, daily, Starting S+1 30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients with CrCL LESS than 30 mL/min. 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients with CrCL LESS than 30 mL/min. 40 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min.
() () () () () () ()	High Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response) Patient is currently receiving therapeutic anticoagulation  Contraindications exist for pharmacologic prophylaxis  apixaban (ELIQUIS) tablet  aspirin chewable tablet aspirin (ECOTRIN) enteric coated tablet enoxaparin (LOVENOX) injection (Single Response) enoxaparin (LOVENOX) syringe - hip arthoplasty  enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min - knee/hip arthroplasty  enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min  enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 2.5 mg, oral, every 12 hours, Starting S+1 Indications: 162 mg, oral, daily, Starting S+1 162 mg, oral, daily, Starting S+1 162 mg, oral, daily, Starting S+1 30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients with CrCL LESS than 30 mL/min. 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min. 40 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min.
	High Risk Pharmacological Prophylaxis - Hip or Knee Arthroplasty) Surgical Patient (Single Response)  Patient is currently receiving therapeutic anticoagulation  Contraindications exist for pharmacologic prophylaxis  apixaban (ELIQUIS) tablet  aspirin chewable tablet aspirin (ECOTRIN) enteric coated tablet enoxaparin (LOVENOX) injection (Single Response) enoxaparin (LOVENOX) syringe - hip arthoplasty  enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min - knee/hip arthroplasty  enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min  enoxaparin (LOVENOX) syringe - For Patients weight	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): 2.5 mg, oral, every 12 hours, Starting S+1 Indications: 162 mg, oral, daily, Starting S+1 162 mg, oral, daily, Starting S+1 162 mg, oral, daily, Starting S+1 30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients with CrCL LESS than 30 mL/min. 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients with CrCL LESS than 30 mL/min. 40 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min.

() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, Starting S+1  If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min  This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM
( ) heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
( ) rivaroxaban (XARELTO) tablet for hip or knee arthroplasty planned during this admission	10 mg, oral, daily at 0600 (time critical), Starting S+1 To be Given on Post Op Day 1. Indications:
() warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical), Starting S+1 Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
[] Mechanical Prophylaxis (Single Response)	
() Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s):
( ) Place/Maintain sequential compression device continuous	Routine, Continuous
() Place sequential compression device and antiembolic stockings	"And" Linked Panel
[] Place/Maintain sequential compression device continuous	Routine, Continuous
[] Place antiembolic stockings	Routine, Once

## **DVT Risk and Prophylaxis Tool (Single Response)**

Low Risk Definition Moderate Risk Definition

Pharmacologic prophylaxis must be addressed. Mechanical prophylaxis is optional unless pharmacologic is contraindicated. High Risk Definition

Both pharmacologic AND mechanical prophylaxis must be addressed.

Age less than 60 years and NO other VTE risk factors One or more of the following medical conditions: One or more of the following medical conditions:

Patient already adequately anticoagulated CHF, MI, lung disease, pneumonia, active inflammation, dehydration, varicose veins, cancer, sepsis, obesity, previous stroke, rheumatologic disease, sickle cell disease, leg swelling, ulcers, venous stasis and nephrotic syndrome Thrombophilia (Factor V Leiden, prothrombin variant mutations, anticardiolipin antibody syndrome; antithrombin, protein C or protein S deficiency; hyperhomocysteinemia; myeloproliferative disorders)

Age 60 and above Severe fracture of hip, pelvis or leg

Central line Acute spinal cord injury with paresis

History of DVT or family history of VTE Multiple major traumas

Anticipated length of stay GREATER than 48 hours Abdominal or pelvic surgery for CANCER

Less than fully and independently ambulatory Acute ischemic stroke

Estrogen therapy History of PE

Moderate or major surgery (not for cancer)

Major surgery within 3 months of admission

() Low Risk of DVT	
[] Low Risk (Single Response)	
( ) Low risk of VTE	Routine, Once Low risk: Due to low risk, no VTE prophylaxis is needed. Will encourgae early ambulation
() Moderate Risk of DVT - Surgical	

Address pharmacologic prophylaxis by selecting one of the following. Mechanical prophylaxis is optional unless pharmacologic prophylaxis is contraindicated.			
Moderate Risk			
Moderate risk of VTE	Routine, Once		
[] Moderate Risk Pharmacological Prophylaxis - Surgical Patient (Single Response)			
() Patient is currently receiving therapeutic anticoagulation	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following:		
() Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):		
( ) enoxaparin (LOVENOX) injection (Single Response)			
( ) enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1		
() enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 For Patients with CrCL LESS than 30 mL/min		
() enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min	30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min		
() enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min	40 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min		
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):		
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM		
() heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.		
() warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical), Starting S+1 Indication:		
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:		
) Moderate Risk of DVT - Non-Surgical			
Address pharmacologic prophylaxis by selecting one of the following. Mechanical prophylaxis is optional unless pharmacologic prophylaxis is contraindicated.			
[] Moderate Risk			
[] Moderate risk of VTE	Routine, Once		
[] Moderate Risk Pharmacological Prophylaxis - Non-Surgical Patient (Single Response)	·		
() Patient is currently receiving therapeutic anticoagulation	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following:		
() Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):		
( ) enoxaparin (LOVENOX) injection (Single Response)			

()	enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 1700 (time critical), Starting S+1
()	enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 1700 (time critical), Starting S+1
		For Patients with CrCL LESS than 30 mL/min
()	enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min	30 mg, subcutaneous, every 12 hours at 0900, 2100 (time critical), Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
()	enoxaparin (LOVENOX) syringe - For Patients weight	40 mg, subcutaneous, every 12 hours at 0900, 2100 (time
()	140 kg or GREATER and CrCl GREATER than 30	critical), Starting S+1
	mL/min	For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min
( )	fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily
		If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT), do NOT orde
		this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min
		This patient has a history of or suspected case of
		Heparin-Induced Thrombocytopenia (HIT):
( )	heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours
	heparin (porcine) injection (Recommended for patients	5,000 Units, subcutaneous, every 12 hours
	with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
()	warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical) Indication:
()	Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
Higl	h Risk of DVT - Surgical	
۸۵۵	lress both pharmacologic and mechanical prophylaxis by orc	dering from Pharmacological and Machanical Prophylavis

[1 High Disk	
[] High Risk [] High risk of VTE	Routine, Once
[] High Risk Pharmacological Prophylaxis - Surgical Patient (Single Response)	
() Patient is currently receiving therapeutic anticoagulation	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following:
() Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
() enoxaparin (LOVENOX) injection (Single Response)	
() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1
() enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 For Patients with CrCL LESS than 30 mL/min
() enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min	30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
() enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min	40 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min

()	fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min.
		This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
()	heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM
()	heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
()	warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical), Starting S+1 Indication:
()	Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
Hig	h Risk of DVT - Non-Surgical	
	dress both pharmacologic and mechanical prophylaxis by ord	dering from Pharmacological and Mechanical Prophylaxis.
	High Risk High risk of VTE	Routine, Once
	High Risk Pharmacological Prophylaxis - Non-Surgical Patient (Single Response)	Houtine, Once
	Patient is currently receiving therapeutic anticoagulation	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following:
()	Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
( )	enoxaparin (LOVENOX) injection (Single Response)	· ·
()	enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily, Starting S+1
()	enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily, Starting S+1 For Patients with CrCL LESS than 30 mL/min
()	enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min	30 mg, subcutaneous, every 12 hours at 0900, 2100 (time critical), Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
()	enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min	40 mg, subcutaneous, every 12 hours at 0900, 2100 (time critical) For Patients weight 140 kg or GREATER and CrCl
()	fondaparinux (ARIXTRA) injection	GREATER than 30 mL/min  2.5 mg, subcutaneous, daily If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min.  This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
()	heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours
$\overline{()}$	heparin (porcine) injection (Recommended for patients	5,000 Units, subcutaneous, every 12 hours Recommended for patients with high risk of bleeding, e.g.
( )	with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	
()	75yrs) warfarin (COUMADIN) tablet	weight LESS than 50kg and age GREATER than 75yrs. oral, daily at 1700 (time critical) Indication:

<sup>()</sup> High Risk of DVT - Surgical (Hip/Knee)

Address both pharmacologic and mechanical prophylaxis by ordering from Pharmacological and Mechanical Prophylaxis.

] High Risk	
High risk of VTE	Routine, Once
High Risk Pharmacological Prophylaxis - Hip or Knee	Houtine, Once
(Arthroplasty) Surgical Patient (Single Response)	
( ) Patient is currently receiving therapeutic anticoagulation	Routine, Once
() I allow to during rossiving morapouts and suggestion	No pharmacologic VTE prophylaxis because: patient is
	already on therapeutic anticoagulation for other indication.
	Therapy for the following:
() Contraindications exist for pharmacologic prophylaxis	Routine, Once
	No pharmacologic VTE prophylaxis due to the following
	contraindication(s):
() apixaban (ELIQUIS) tablet	2.5 mg, oral, every 12 hours, Starting S+1
	Indications:
( ) aspirin chewable tablet	162 mg, oral, daily, Starting S+1
( ) aspirin (ECOTRIN) enteric coated tablet	162 mg, oral, daily, Starting S+1
( ) enoxaparin (LOVENOX) injection (Single Response)	
( ) enoxaparin (LOVENOX) syringe - hip arthoplasty	40 mg, subcutaneous, daily at 0600 (time critical), Starting
	S+1
() enoxaparin (LOVENOX) syringe - knee arthroplasty	30 mg, subcutaneous, 2 times daily at 0600, 1800 (time
	critical), Starting S+1
() enoxaparin (LOVENOX) syringe - For Patients with CrCL	30 mg, subcutaneous, daily at 0600 (time critical), Starting
LESS than 30 mL/min - knee/hip arthroplasty	S+1
	For Patients with CrCL LESS than 30 mL/min.
() enoxaparin (LOVENOX) syringe - For Patients weight	30 mg, subcutaneous, 2 times daily at 0600, 1800 (time
between 100-139 kg and CrCl GREATER than 30	critical), Starting S+1
mL/min	For Patients weight between 100-139 kg and CrCl
() (, 0) (5) (0) (, 5) (, 5)	GREATER than 30 mL/min.
( ) enoxaparin (LOVENOX) syringe - For Patients weight	40 mg, subcutaneous, 2 times daily at 0600, 1800 (time
140 kg or GREATER and CrCl GREATER than 30 mL/min	critical), Starting S+1
IIIL/IIIIII	For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min
( ) fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, Starting S+1
( ) Torrodomiax (At tixer to t) injustion	If the patient does not have a history or suspected case of
	Heparin-Induced Thrombocytopenia (HIT) do NOT order
	this medication. Contraindicated in patients LESS than
	50kg, prior to surgery/invasive procedure, or CrCl LESS
	than 30 mL/min
	This patient has a history of or suspected case of
	Heparin-Induced Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00
	AM
() heparin (porcine) injection (Recommended for patients	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00
with high risk of bleeding, e.g. weight < 50kg and age >	AM
75yrs)	Recommended for patients with high risk of bleeding, e.g.
(X)	weight LESS than 50kg and age GREATER than 75yrs.
() rivaroxaban (XARELTO) tablet for hip or knee	10 mg, oral, daily at 0600 (time critical), Starting S+1
arthroplasty planned during this admission	To be Given on Post Op Day 1.
() (OOLHMAD!!):	Indications:
() warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical), Starting S+1
( ) Discourse ( ) (OOLBARD)	Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S
	Indication:

**DVT Risk and Prophylaxis Tool (Single Response)** 

Low Risk Definition Moderate Risk Definition

Pharmacologic prophylaxis must be addressed. Mechanical prophylaxis is optional unless pharmacologic is contraindicated. High Risk Definition

Both pharmacologic AND mechanical prophylaxis must be addressed.

Age less than 60 years and NO other VTE risk factors One or more of the following medical conditions: One or more of the following medical conditions:

Patient already adequately anticoagulated CHF, MI, lung disease, pneumonia, active inflammation, dehydration, varicose veins, cancer, sepsis, obesity, previous stroke, rheumatologic disease, sickle cell disease, leg swelling, ulcers, venous stasis and nephrotic syndrome Thrombophilia (Factor V Leiden, prothrombin variant mutations, anticardiolipin antibody syndrome; antithrombin, protein C or protein S deficiency; hyperhomocysteinemia; myeloproliferative disorders)

Age 60 and above Severe fracture of hip, pelvis or leg

Central line Acute spinal cord injury with paresis

History of DVT or family history of VTE Multiple major traumas

Anticipated length of stay GREATER than 48 hours Abdominal or pelvic surgery for CANCER

Less than fully and independently ambulatory Acute ischemic stroke

Estrogen therapy History of PE

Moderate or major surgery (not for cancer)

Major surgery within 3 months of admission

( ) Low Risk of DVT	
[] Low Risk (Single Response)	
() Low risk of VTE	Routine, Once Low risk: Due to low risk, no VTE prophylaxis is needed. Will encourgae early ambulation
() Moderate Risk of DVT - Surgical	
Address pharmacologic prophylaxis by selecting one of the follopharmacologic prophylaxis is contraindicated.	owing. Mechanical prophylaxis is optional unless
[] Moderate Risk	
[] Moderate risk of VTE	Routine, Once
[] Moderate Risk Pharmacological Prophylaxis - Surgical Patient (Single Response)	
() Patient is currently receiving therapeutic anticoagulation	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following:
() Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
( ) enoxaparin (LOVENOX) injection (Single Response)	
( ) enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1
( ) enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 For Patients with CrCL LESS than 30 mL/min
() enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min	30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
() enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min	40 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patient weight of 140 kg or GREATER and CrCl GREATER than 30 mL/min
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min.  This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):

() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM
() heparin (porcine) injection (Recommended for patients	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00
with high risk of bleeding, e.g. weight < 50kg and age >	AM
75yrs)	Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
() warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical), Starting S+1 Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
[] Mechanical Prophylaxis (Single Response)	
() Contraindications exist for mechanical prophylaxis	Routine, Once
	No mechanical VTE prophylaxis due to the following contraindication(s):
( ) Place/Maintain sequential compression device continuous	Routine, Continuous
<ul> <li>Place sequential compression device and antiembolic stockings</li> </ul>	"And" Linked Panel
[] Place/Maintain sequential compression device continuous	Routine, Continuous
[] Place antiembolic stockings	Routine, Once
) Moderate Risk of DVT - Non-Surgical	
Address pharmacologic prophylaxis by selecting one of the follopharmacologic prophylaxis is contraindicated.	owing. Mechanical prophylaxis is optional unless
Moderate Risk	
[] Moderate risk of VTE	Routine, Once
[] Moderate Risk Pharmacological Prophylaxis - Non-Surgical Patient (Single Response)	
() Patient is currently receiving therapeutic anticoagulation	Routine, Once
	No pharmacologic VTE prophylaxis because: patient is
	already on therapeutic anticoagulation for other indication.
( ) Contraindications exist for about a coloris are bulletin	Therapy for the following:
() Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following
	contraindication(s):
() enoxaparin (LOVENOX) injection (Single Response)	· /
() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 1700 (time critical), Starting
() : ((0)/[[10](0)] : [ [ [ [ [ [ [ [ [ [ [ [ [ [ [ [ [ [	S
() enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 1700 (time critical), Starting S
LEGS than 50 me/min	For Patients with CrCL LESS than 30 mL/min
() enoxaparin (LOVENOX) syringe - For Patients weight	30 mg, subcutaneous, 2 times daily, Starting S
between 100-139 kg and CrCl GREATER than 30 mL/min	For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
() enoxaparin (LOVENOX) syringe - For Patients weight	40 mg, subcutaneous, 2 times daily, Starting S
140 kg or GREATER and CrCl GREATER than 30 mL/min	For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily
	If the patient does not have a history of or suspected case
	of Heparin-Induced Thrombocytopenia (HIT), do NOT order this medication. Contraindicated in patients LESS than
	50kg, prior to surgery/invasive procedure, or CrCl LESS
	than 30 mL/min
	This patient has a history of or suspected case of
	Heparin-Induced Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours
() heparin (porcine) injection (Recommended for patients	5,000 Units, subcutaneous, every 12 hours
with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
( ) warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical)
\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	Indication:

()	Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
[]	Mechanical Prophylaxis (Single Response)	THE COLUMN TO TH
()	Contraindications exist for mechanical prophylaxis	Routine, Once
( )	Contrainational oxide for modifical propriytaxio	No mechanical VTE prophylaxis due to the following
		contraindication(s):
()	Place/Maintain sequential compression device	Routine, Continuous
( )	continuous	Troumo, Commodo
()	Place sequential compression device and antiembolic stockings	"And" Linked Panel
ī		Routine, Continuous
_	continuous	<u> </u>
[	, ,	Routine, Once
	gh Risk of DVT - Surgical	
Ad	ldress both pharmacologic and mechanical prophylaxis by or	dering from Pharmacological and Mechanical Prophylaxis.
<u> </u>	Lliah Diak	
11	High Risk High risk of VTE	Routine, Once
[]	High Risk Pharmacological Prophylaxis - Surgical Patient	riodine, Once
	(Single Response)	
()	Patient is currently receiving therapeutic anticoagulation	Routine, Once
( )	The same of the sa	No pharmacologic VTE prophylaxis because: patient is
		already on therapeutic anticoagulation for other indication.
		Therapy for the following:
()	Contraindications exist for pharmacologic prophylaxis	Routine, Once
		No pharmacologic VTE prophylaxis due to the following
		contraindication(s):
( <u>)</u>	enoxaparin (LOVENOX) injection (Single Response)	
(	) enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1
(	) enoxaparin (LOVENOX) syringe - For Patients with CrCL	30 mg, subcutaneous, daily at 0600 (time critical), Starting
	LESS than 30 mL/min	S+1
_		For Patients with CrCL LESS than 30 mL/min
(	enoxaparin (LOVENOX) syringe - For Patients weight	30 mg, subcutaneous, 2 times daily at 0600, 1800 (time
	between 100-139 kg and CrCl GREATER than 30	critical), Starting S+1
	mL/min	For Patients weight between 100-139 kg and CrCl
_	) anavanarin (LOVENOV) avringa. For Patienta weight	GREATER than 30 mL/min
(	) enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30	40 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1
	mL/min	For Patients weight 140 kg or GREATER and CrCl
	1112111111	GREATER than 30 mL/min
()	fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, Starting S+1
( )	Torroaparmax (XIIIIXTTI II) Injocion	If the patient does not have a history or suspected case of
		Heparin-Induced Thrombocytopenia (HIT) do NOT order
		this medication. Contraindicated in patients LESS than
		50kg, prior to surgery/invasive procedure, or CrCl LESS
		than 30 mL/min.
		This patient has a history of or suspected case of
		Heparin-Induced Thrombocytopenia (HIT):
( )	heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM
()	heparin (porcine) injection (Recommended for patients	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00
	with high risk of bleeding, e.g. weight < 50kg and age >	AM
	75yrs)	Recommended for patients with high risk of bleeding, e.g.
_		weight LESS than 50kg and age GREATER than 75yrs.
()	warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical), Starting S+1 Indication:
()	Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S
		Indication:
[1	Mechanical Prophylaxis (Single Response)	

() Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s):
( ) Place/Maintain sequential compression device continuous	Routine, Continuous
Place sequential compression device and antiembolic stockings	"And" Linked Panel
[] Place/Maintain sequential compression device continuous	Routine, Continuous
[] Place antiembolic stockings	Routine, Once
) High Risk of DVT - Non-Surgical	
Address both pharmacologic and mechanical prophylaxis by ord	dering from Pharmacological and Mechanical Prophylaxis.
[ ] High Risk	
[] High risk of VTE	Routine, Once
[] High Risk Pharmacological Prophylaxis - Non-Surgical Patient (Single Response)	
() Patient is currently receiving therapeutic anticoagulation	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication.
	Therapy for the following:
() Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
() enoxaparin (LOVENOX) injection (Single Response)	
() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 1700 (time critical), Starting S
() enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 1700 (time critical), Starting S For Patients with CrCL LESS than 30 mL/min
() enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min	30 mg, subcutaneous, 2 times daily, Starting S For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
<ul><li>( ) enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min</li></ul>	40 mg, subcutaneous, 2 times daily, Starting S For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours
<ul><li>() heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight &lt; 50kg and age &gt; 75yrs)</li></ul>	5,000 Units, subcutaneous, every 12 hours Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
() warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical) Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
[] Mechanical Prophylaxis (Single Response)	
() Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s):
( ) Place/Maintain sequential compression device continuous	Routine, Continuous
() Place sequential compression device and antiembolic stockings	"And" Linked Panel
[] Place/Maintain sequential compression device continuous	Routine, Continuous

[] Place antiembolic stockings	Routine, Once
) High Risk of DVT - Surgical (Hip/Knee)	
Address both pharmacologic and mechanical prophylaxis by or	dering from Pharmacological and Mechanical Prophylaxis.
[] High Risk	
[] High risk of VTE	Routine, Once
[] High Risk Pharmacological Prophylaxis - Hip or Knee (Arthroplasty) Surgical Patient (Single Response)	
() Patient is currently receiving therapeutic anticoagulation	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following:
() Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
( ) apixaban (ELIQUIS) tablet	2.5 mg, oral, every 12 hours, Starting S+1 Indications:
() aspirin chewable tablet	162 mg, oral, daily, Starting S+1
() aspirin (ECOTRIN) enteric coated tablet	162 mg, oral, daily, Starting S+1
() enoxaparin (LOVENOX) injection (Single Response)	
() enoxaparin (LOVENOX) syringe - hip arthoplasty	40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1
() enoxaparin (LOVENOX) syringe - knee arthroplasty	30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1
() enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min - knee/hip arthroplasty	30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 For Patients with CrCL LESS than 30 mL/min.
() enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min	30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min.
() enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min	40 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM
() heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
( ) rivaroxaban (XARELTO) tablet for hip or knee arthroplasty planned during this admission	10 mg, oral, daily at 0600 (time critical), Starting S+1 To be Given on Post Op Day 1. Indications:
() warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical), Starting S+1 Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
[] Mechanical Prophylaxis (Single Response)	
() Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s):
( ) Place/Maintain sequential compression device continuous	Routine, Continuous

( ) Place sequential compression device and antiemboli	c "And" Linked Panel
stockings  [ ] Place/Maintain sequential compression device	Routine, Continuous
continuous  [ ] Place antiembolic stockings	Routine, Once
[] These analysis steelings	Tiouline, Olice
_abs	
General	
	0
CBC and differential	Once
] Hematocrit	Once, Starting S For 1 Occurrences
<ul><li>Hemoglobin</li><li>Platelet count</li></ul>	Once
•	Once
Comprehensive metabolic panel	Once
Basic metabolic panel     BUN	Once
1 Creatinine	Once Once
Hepatic function panel     Amylase	Once Once
] Amylase ] Erythropoietin	Once
Sedimentation rate	Once
Lactate dehydrogenase, LDH	Once
Lipase	Once
Bilirubin, direct	Once
Bilirubin, total	Once
GGT	Once
] Magnesium	Once
Calcium	Once
Urinalysis with microscopic	Once
C-reactive protein	Once
FK506 Tacrolimus level, random	Once
CLO test	Once, Biopsy
Cyclosporine level, random	Once
Protein electrophoresis, serum	Once
Phosphorus	Once
CK isoenzymes	Once
Prealbumin	Once
Prothrombin time with INR	Once
Partial thromboplastin time	Once
PTH-related peptide	Once
Rheumatoid factor	Once
Syphilis treponemal IgG	Once
General - HMSJ	
] CBC and differential	Once
] Hematocrit	Once, Starting S For 1 Occurrences
] Hemoglobin	Once
Platelet count	Once
Comprehensive metabolic panel	Once
Basic metabolic panel	Once
BUN	Once
] Creatinine	Once
Hepatic function panel	Once
] Amylase	Once
] Erythropoietin	Once
] Sedimentation rate	Once
Lactate dehydrogenase, LDH	Once
] Lipase	Once

Once

[] Bilirubin, direct

I	
[] Bilirubin, total	Once
[] GGT	Once
[] Magnesium	Once
[] Calcium	Once
[] Urinalysis with microscopic	Once
[] C-reactive protein	Once
[] FK506 Tacrolimus level, random	Once
[] CLO test	Once, Biopsy
<u> </u>	Once
[] Cyclosporine level, random	
Protein electrophoresis, serum	Once
[] Phosphorus	Once
[] CK isoenzymes	Once
[] Prealbumin	Once
[] Prothrombin time with INR	Once
[] Partial thromboplastin time	Once
[] PTH-related peptide	Once
Rheumatoid factor qual	Once
Rheumatoid factor titer	Once
[] Syphilis treponemal IgG	Once
[] Syprims reporternal ige	
Metabolic	
[] Hemoglobin A1c	Once
[] Lipid panel	Once
[] Testosterone	Once
[] TSH	Once
[] T3	Once
[] T4	Once
[] Ferritin	Once
[] Iron	Once
[] Total iron binding capacity	Once
[] PSA	Once
[] Transferrin	Once
L J	Once
[] Ceruloplasmin	
[] Cryo, globulin and fibrinogen	Once
[] Alpha-1-antitrypsin	Once
[] Alpha-1 antitrypsin phenotype	Once
[] Uric acid	Once
[] Vitamin A	Once
[] Vitamin B12	Once
[] Folate	Once
[] Vitamin D 25 hydroxy	Once
[] Vitamin E	Once
[] Zinc	Once
[] GGT	Once
[] Haptoglobin	Once
[] Troponin I	Once
[] CK total	Once
[] Carnitine, free and total	Once
[] B-type natriuretic peptide	Once
[] Ammonia	Once
Viral Workup - HMH	
[] Cytomegalovirus antibody, IgG	Once
[] Cytomegalovirus antibody, IgM	Once
	Once
[] Cytomegalovirus (CMV), PCR	Specimen Source: Plasma
[1] Cytomog IgG/IgM	Once
[] Cytomeg IgG/IgM	
[] Epstein-Barr virus antibody test	Once

[1] Francis Daw Visus (FDV) by DOD	
[] Epstein Barr Virus (EBV) by PCR	Once
	Specimen Source: Plasma
[] HIV Ag/Ab combination	Once
[] Hepatitis A antibody, total	Once
[] Hepatitis A antibody, IgM	Once
[] Hepatitis B core antibody, IgM	Once
5. 1	
[] Hepatitis B core antibody, total	Once
[] Hepatitis B e antibody	Once
[] Hepatitis B e antigen	Once
[] Hepatitis B surface antibody	Once
[] Hepatitis B surface Ab, quantitative	Once
[] Hepatitis B surface antigen	Once
[] HBV quantitative, PCR	Once
[] Hepatitis C antibody	Once
[] Hepatitis C genotype	Once
[] Hepatitis C quantitative, PCR	Once
[] Hepatitis delta virus	Once
[] Hepatitis delta virus (HDV) Ab, IgM	Once
[] Hepatitis E virus Ab, IgG by ELISA	Once
[] Hepatitis E virus Ab, IgM by ELISA	Once
[] Herpes simplex virus, PCR	Once
,	Specimen Source: Plasma
	-p
Viral Workup - HMSL/HMW	
[] Cytomegalovirus antibody, IgG	Once
[] Cytomegalovirus antibody, IgM	Once
[] Cytomegalovirus (CMV), PCR	Once
	Specimen Source: Plasma
[] Cytomeg lgG/lgM	Once
[] Epstein-Barr virus antibody test	Once
[] Epstein Barr Virus (EBV) by PCR	Once
[] Epotoni Ban vindo (EBV) by i Ort	Specimen Source: Plasma
[] Rapid HIV 1 & 2	Once
[] Hepatitis A antibody, total	
	Once
[] Hepatitis A antibody, IgM	Once
[] Hepatitis B core antibody, IgM	Once
[] Hepatitis B core antibody, IgM [] Hepatitis B core antibody, total	Once
[] Hepatitis B core antibody, total	Once
Hepatitis B core antibody, total   Hepatitis B e antibody   Hepatitis B e antigen	Once Once Once
<ul> <li>[] Hepatitis B core antibody, total</li> <li>[] Hepatitis B e antibody</li> <li>[] Hepatitis B e antigen</li> <li>[] Hepatitis B surface antibody</li> </ul>	Once Once Once Once
<ul> <li>Hepatitis B core antibody, total</li> <li>Hepatitis B e antibody</li> <li>Hepatitis B e antigen</li> <li>Hepatitis B surface antibody</li> <li>Hepatitis B surface Ab, quantitative</li> </ul>	Once Once Once Once Once Once
<ul> <li>[] Hepatitis B core antibody, total</li> <li>[] Hepatitis B e antibody</li> <li>[] Hepatitis B surface antibody</li> <li>[] Hepatitis B surface Ab, quantitative</li> <li>[] Hepatitis B surface antibed</li> </ul>	Once Once Once Once Once Once Once
[] Hepatitis B core antibody, total [] Hepatitis B e antibody [] Hepatitis B e antigen [] Hepatitis B surface antibody [] Hepatitis B surface Ab, quantitative [] Hepatitis B surface antigen [] HBV quantitative, PCR	Once Once Once Once Once Once Once Once
[] Hepatitis B core antibody, total [] Hepatitis B e antibody [] Hepatitis B e antigen [] Hepatitis B surface antibody [] Hepatitis B surface Ab, quantitative [] Hepatitis B surface antigen [] HBV quantitative, PCR [] Hepatitis C antibody	Once Once Once Once Once Once Once Once
[] Hepatitis B core antibody, total [] Hepatitis B e antibody [] Hepatitis B e antigen [] Hepatitis B surface antibody [] Hepatitis B surface Ab, quantitative [] Hepatitis B surface antigen [] HBV quantitative, PCR [] Hepatitis C antibody [] Hepatitis C genotype	Once Once Once Once Once Once Once Once
[] Hepatitis B core antibody, total [] Hepatitis B e antibody [] Hepatitis B surface antibody [] Hepatitis B surface Ab, quantitative [] Hepatitis B surface antigen [] HBV quantitative, PCR [] Hepatitis C antibody [] Hepatitis C genotype [] Hepatitis C quantitative, PCR	Once Once Once Once Once Once Once Once
[] Hepatitis B core antibody, total [] Hepatitis B e antibody [] Hepatitis B e antigen [] Hepatitis B surface antibody [] Hepatitis B surface Ab, quantitative [] Hepatitis B surface antigen [] HBV quantitative, PCR [] Hepatitis C antibody [] Hepatitis C genotype	Once Once Once Once Once Once Once Once
[] Hepatitis B core antibody, total [] Hepatitis B e antibody [] Hepatitis B surface antibody [] Hepatitis B surface Ab, quantitative [] Hepatitis B surface antigen [] HBV quantitative, PCR [] Hepatitis C antibody [] Hepatitis C genotype [] Hepatitis C quantitative, PCR	Once Once Once Once Once Once Once Once
[] Hepatitis B core antibody, total [] Hepatitis B e antibody [] Hepatitis B e antigen [] Hepatitis B surface antibody [] Hepatitis B surface Ab, quantitative [] Hepatitis B surface antigen [] HBV quantitative, PCR [] Hepatitis C antibody [] Hepatitis C genotype [] Hepatitis C quantitative, PCR [] Hepatitis delta virus [] Hepatitis delta virus (HDV) Ab, IgM	Once Once Once Once Once Once Once Once
[] Hepatitis B core antibody, total [] Hepatitis B e antibody [] Hepatitis B e antigen [] Hepatitis B surface antibody [] Hepatitis B surface Ab, quantitative [] Hepatitis B surface antigen [] HBV quantitative, PCR [] Hepatitis C antibody [] Hepatitis C genotype [] Hepatitis C quantitative, PCR [] Hepatitis C quantitative, PCR [] Hepatitis delta virus [] Hepatitis delta virus (HDV) Ab, IgM [] Hepatitis E virus Ab, IgG by ELISA	Once Once Once Once Once Once Once Once
[] Hepatitis B core antibody, total [] Hepatitis B e antibody [] Hepatitis B e antigen [] Hepatitis B surface antibody [] Hepatitis B surface Ab, quantitative [] Hepatitis B surface antigen [] HBV quantitative, PCR [] Hepatitis C antibody [] Hepatitis C genotype [] Hepatitis C quantitative, PCR [] Hepatitis delta virus [] Hepatitis delta virus [] Hepatitis E virus Ab, IgG by ELISA [] Hepatitis E virus Ab, IgM by ELISA	Once Once Once Once Once Once Once Once
[] Hepatitis B core antibody, total [] Hepatitis B e antibody [] Hepatitis B e antigen [] Hepatitis B surface antibody [] Hepatitis B surface Ab, quantitative [] Hepatitis B surface antigen [] HBV quantitative, PCR [] Hepatitis C antibody [] Hepatitis C genotype [] Hepatitis C quantitative, PCR [] Hepatitis C quantitative, PCR [] Hepatitis delta virus [] Hepatitis delta virus (HDV) Ab, IgM [] Hepatitis E virus Ab, IgG by ELISA	Once Once Once Once Once Once Once Once
[] Hepatitis B core antibody, total [] Hepatitis B e antibody [] Hepatitis B e antigen [] Hepatitis B surface antibody [] Hepatitis B surface Ab, quantitative [] Hepatitis B surface antigen [] HBV quantitative, PCR [] Hepatitis C antibody [] Hepatitis C genotype [] Hepatitis C quantitative, PCR [] Hepatitis delta virus [] Hepatitis delta virus [] Hepatitis E virus Ab, IgG by ELISA [] Hepatitis E virus Ab, IgM by ELISA	Once Once Once Once Once Once Once Once
[] Hepatitis B core antibody, total [] Hepatitis B e antibody [] Hepatitis B surface antibody [] Hepatitis B surface Ab, quantitative [] Hepatitis B surface antigen [] HBV quantitative, PCR [] Hepatitis C antibody [] Hepatitis C genotype [] Hepatitis C quantitative, PCR [] Hepatitis C quantitative, PCR [] Hepatitis delta virus [] Hepatitis delta virus [] Hepatitis E virus Ab, IgG by ELISA [] Hepatitis E virus Ab, IgM by ELISA [] Herpes simplex virus, PCR	Once Once Once Once Once Once Once Once
[] Hepatitis B core antibody, total [] Hepatitis B e antibody [] Hepatitis B e antigen [] Hepatitis B surface antibody [] Hepatitis B surface Ab, quantitative [] Hepatitis B surface antigen [] HBV quantitative, PCR [] Hepatitis C antibody [] Hepatitis C genotype [] Hepatitis C quantitative, PCR [] Hepatitis delta virus [] Hepatitis delta virus [] Hepatitis E virus Ab, IgG by ELISA [] Hepatitis E virus Ab, IgM by ELISA	Once Once Once Once Once Once Once Once
[] Hepatitis B core antibody, total [] Hepatitis B e antibody [] Hepatitis B surface antibody [] Hepatitis B surface Ab, quantitative [] Hepatitis B surface antigen [] HBV quantitative, PCR [] Hepatitis C antibody [] Hepatitis C genotype [] Hepatitis C quantitative, PCR [] Hepatitis G quantitative, PCR [] Hepatitis Gelta virus [] Hepatitis delta virus [] Hepatitis E virus Ab, IgG by ELISA [] Hepatitis E virus Ab, IgM by ELISA [] Herpes simplex virus, PCR	Once Once Once Once Once Once Once Once
[] Hepatitis B core antibody, total [] Hepatitis B e antibody [] Hepatitis B surface antibody [] Hepatitis B surface Ab, quantitative [] Hepatitis B surface antigen [] HBV quantitative, PCR [] Hepatitis C antibody [] Hepatitis C genotype [] Hepatitis C quantitative, PCR [] Hepatitis delta virus [] Hepatitis delta virus [] Hepatitis delta virus (HDV) Ab, IgM [] Hepatitis E virus Ab, IgG by ELISA [] Hepatitis E virus Ab, IgM by ELISA [] Herpes simplex virus, PCR  Viral Workup - HMSTJ, HMTW, HMSJ, HMWB [] Cytomegalovirus antibody, IgG	Once Once Once Once Once Once Once Once
[] Hepatitis B core antibody, total [] Hepatitis B e antibody [] Hepatitis B surface antibody [] Hepatitis B surface Ab, quantitative [] Hepatitis B surface antigen [] HBV quantitative, PCR [] Hepatitis C antibody [] Hepatitis C genotype [] Hepatitis C quantitative, PCR [] Hepatitis G quantitative, PCR [] Hepatitis delta virus [] Hepatitis delta virus [] Hepatitis E virus Ab, IgG by ELISA [] Hepatitis E virus Ab, IgM by ELISA [] Herpes simplex virus, PCR  Viral Workup - HMSTJ, HMTW, HMSJ, HMWB [] Cytomegalovirus antibody, IgG [] Cytomegalovirus antibody, IgM	Once Once Once Once Once Once Once Once
[] Hepatitis B core antibody, total [] Hepatitis B e antibody [] Hepatitis B surface antibody [] Hepatitis B surface Ab, quantitative [] Hepatitis B surface antigen [] HBV quantitative, PCR [] Hepatitis C antibody [] Hepatitis C genotype [] Hepatitis C quantitative, PCR [] Hepatitis delta virus [] Hepatitis delta virus [] Hepatitis delta virus (HDV) Ab, IgM [] Hepatitis E virus Ab, IgG by ELISA [] Hepatitis E virus Ab, IgM by ELISA [] Herpes simplex virus, PCR  Viral Workup - HMSTJ, HMTW, HMSJ, HMWB [] Cytomegalovirus antibody, IgG	Once Once Once Once Once Once Once Once
[] Hepatitis B core antibody, total [] Hepatitis B e antibody [] Hepatitis B surface antibody [] Hepatitis B surface Ab, quantitative [] Hepatitis B surface antigen [] HBV quantitative, PCR [] Hepatitis C antibody [] Hepatitis C genotype [] Hepatitis C quantitative, PCR [] Hepatitis C quantitative, PCR [] Hepatitis delta virus [] Hepatitis delta virus [] Hepatitis E virus Ab, IgG by ELISA [] Hepatitis E virus Ab, IgM by ELISA [] Herpes simplex virus, PCR  Viral Workup - HMSTJ, HMTW, HMSJ, HMWB [] Cytomegalovirus antibody, IgG [] Cytomegalovirus antibody, IgM	Once Once Once Once Once Once Once Once

1	
[] Epstein-Barr virus antibody test	Once
[] Epstein Barr Virus (EBV) by PCR	Once
	Specimen Source: Plasma
[] HIV 1, 2 antibody	Once
[] Hepatitis A antibody, total	Once
[] Hepatitis A antibody, IgM	Once
[] Hepatitis B core antibody, IgM	Once
[] Hepatitis B core antibody, total	Once
[] Hepatitis B e antibody	Once
[] Hepatitis B e antigen	Once
[] Hepatitis B surface antibody	Once
[] Hepatitis B surface Ab, quantitative	Once
[] Hepatitis B surface antigen	Once
[] HBV quantitative, PCR	Once
[] Hepatitis C antibody	Once
	Once
[] Hepatitis C genotype	
[] Hepatitis C quantitative, PCR	Once
[] Hepatitis delta virus	Once
[] Hepatitis delta virus (HDV) Ab, IgM	Once
[] Hepatitis E virus Ab, IgG by ELISA	Once
[] Hepatitis E virus Ab, IgM by ELISA	Once
[] Herpes simplex virus, PCR	Once
	Specimen Source: Plasma
Autoimmune Workup	
[] Anti-smooth muscle antibody titer	Once
[] Gliadin antibodies, serum	Once
[] Tissue transglutaminase, IgA	Once
[] Tissue transglutaminase, IgG	Once
[] Liver-kidney-microsome Ab, IgG	Once
[] ANA	Once
[] Antimitochondrial antibody	Once
[] IgG, IgA, IgM	Once
[] IgE	Once
One on Western	
Cancer Workup	
[] Alpha fetoprotein	Once
[] CEA	Once
[] Cancer antigen 19-9	Once
[] CA 125	Once
[] Chromogranin A	Once
[] Gastrin	Once
[] dastiiii	Office
Copper Studies	
[] Ceruloplasmin	Once
[] Copper, serum	Once
[] Copper, urine	Once
Stool Studies	
Occult blood, stool	Conditional Frequency For 3 Occurrences, Stool
[1] 555311 51554, 51551	When specimen available
[] Stool culture	Once For 1 Occurrences, Stool
[] Ova & Parasites-Concentrated Examination	Once, Stool
**	Once, Stool
[] Fecal leukocytes smear	·
[] Giardia antigen	Once, Stool
[] Potassium, stool	Once, Starting S For 1 Occurrences, Stool
[] Sodium, stool [] Fecal fat, qualitative	Once, Starting S For 1 Occurrences, Stool
	Once, Stool

[1] Countries and in the action of the countries of the c	Once Charl
[] Cryptosporidium antigen, stool [] Porphyrin, total	Once, Stool Once
[] Porphyrin, total  Misc Referral Lab Test	Office
Hemochromatosis (HFE) 3 mutations	Once
[] Hepatitis B virus DNA, Qualitative	Once Hepatitis B virus DNA, Qualitative
[] DCP (PIVKA II)	Once DCP (PIVKA II)
[] AFP-L3%	Once AFP-L3%
Microbiology	
[] Blood culture x 2	"And" Linked Panel
[] Blood Culture (Aerobic & Anaerobic)	Once, Blood Collect before antibiotics given. Blood cultures should be ordered x2, with each set drawn from a different peripheral site. If unable to draw both sets from a peripheral site, please call the lab for assistance; an IV line should NEVER be used.
[] Blood Culture (Aerobic & Anaerobic)	Once, Blood Collect before antibiotics given. Blood cultures should be ordered x2, with each set drawn from a different peripheral site. If unable to draw both sets from a peripheral site, please call the lab for assistance; an IV line should NEVER be used.
Cardiology	
Cardiology	
[] Echocardiogram with agitated saline	Routine, 1 time imaging
Diagnostic Imaging	
СТ	
[] CT Abdomen W/WO Contrast (Omnipaque)	"And" Linked Panel
For those with iodine allergies, please order the panel with	Readi-Cat (barium sulfate).
[] CT Abdomen W Wo Contrast	Routine, 1 time imaging For 1
[] iohexol (OMNIPAQUE) 300 mg iodine/mL oral solution	Liver protocol
I   I   I   I   I   I   I   I	Liver protocol 30 mL, oral, once
[] CT Chest Wo Contrast	Liver protocol 30 mL, oral, once Routine, 1 time imaging For 1
, , ,	30 mL, oral, once
[] CT Chest Wo Contrast  MRI/MRA	30 mL, oral, once Routine, 1 time imaging For 1
[] CT Chest Wo Contrast  MRI/MRA  [] MRI Abdomen W Wo Contrast	30 mL, oral, once Routine, 1 time imaging For 1  Routine, 1 time imaging For 1  Gadolinium contrast
[] CT Chest Wo Contrast  MRI/MRA	30 mL, oral, once Routine, 1 time imaging For 1  Routine, 1 time imaging For 1
[] CT Chest Wo Contrast  MRI/MRA  [] MRI Abdomen W Wo Contrast  [] MRI Abdomen W Wo Contrast  [] MRI Cholangiogram	30 mL, oral, once Routine, 1 time imaging For 1  Routine, 1 time imaging For 1 Gadolinium contrast Routine, 1 time imaging For 1 EOVIST contrast Routine, 1 time imaging For 1
[] CT Chest Wo Contrast  MRI/MRA  [] MRI Abdomen W Wo Contrast  [] MRI Abdomen W Wo Contrast	30 mL, oral, once Routine, 1 time imaging For 1  Routine, 1 time imaging For 1 Gadolinium contrast Routine, 1 time imaging For 1 EOVIST contrast
[] CT Chest Wo Contrast  MRI/MRA  [] MRI Abdomen W Wo Contrast  [] MRI Abdomen W Wo Contrast  [] MRI Cholangiogram	30 mL, oral, once Routine, 1 time imaging For 1  Routine, 1 time imaging For 1 Gadolinium contrast Routine, 1 time imaging For 1 EOVIST contrast Routine, 1 time imaging For 1
[] CT Chest Wo Contrast  MRI/MRA  [] MRI Abdomen W Wo Contrast  [] MRI Cholangiogram [] MRI Bone Survey  X-Ray  [] CHEST 2 VW	30 mL, oral, once Routine, 1 time imaging For 1  Routine, 1 time imaging For 1 Gadolinium contrast Routine, 1 time imaging For 1 EOVIST contrast Routine, 1 time imaging For 1 Routine, 1 time imaging For 1 Routine, 1 time imaging For 1
[] CT Chest Wo Contrast  MRI/MRA  [] MRI Abdomen W Wo Contrast  [] MRI Abdomen W Wo Contrast  [] MRI Cholangiogram [] MRI Bone Survey  X-Ray	30 mL, oral, once Routine, 1 time imaging For 1  Routine, 1 time imaging For 1 Gadolinium contrast Routine, 1 time imaging For 1 EOVIST contrast Routine, 1 time imaging For 1 Routine, 1 time imaging For 1
[] CT Chest Wo Contrast  MRI/MRA  [] MRI Abdomen W Wo Contrast  [] MRI Cholangiogram [] MRI Bone Survey  X-Ray  [] CHEST 2 VW	30 mL, oral, once Routine, 1 time imaging For 1  Routine, 1 time imaging For 1 Gadolinium contrast Routine, 1 time imaging For 1 EOVIST contrast Routine, 1 time imaging For 1 Routine, 1 time imaging For 1 Routine, 1 time imaging For 1
[] CT Chest Wo Contrast  MRI/MRA  [] MRI Abdomen W Wo Contrast  [] MRI Cholangiogram [] MRI Bone Survey  X-Ray  [] CHEST 2 VW [] Upper GI and Small Bowel  US  [] US Abdomen Complete	30 mL, oral, once Routine, 1 time imaging For 1  Routine, 1 time imaging For 1 Gadolinium contrast Routine, 1 time imaging For 1 EOVIST contrast Routine, 1 time imaging For 1
[] CT Chest Wo Contrast  MRI/MRA  [] MRI Abdomen W Wo Contrast  [] MRI Cholangiogram [] MRI Bone Survey  X-Ray  [] CHEST 2 VW [] Upper GI and Small Bowel  US	30 mL, oral, once Routine, 1 time imaging For 1  Routine, 1 time imaging For 1 Gadolinium contrast Routine, 1 time imaging For 1 EOVIST contrast Routine, 1 time imaging For 1

] US Abdominal Doppler	Routine, 1 time imaging For 1
Other Diagnostic Studies	
Other Diagnostic Studies	
] NM Hepatobiliary	Routine, 1 time imaging For 1
] NM Gastric Emptying	Routine, 1 time imaging For 1 4 hours
] IR Consult To Interventional Radiology	Routine, 1 time imaging For 1
] Image Guidance Biopsy	Transjugular liver biopsy with portal pressure measurements Routine, 1 time imaging For 1
Respiratory	
Rehab	
Consults	
Physician Consults	
] Consult Hepatology	Reason for Consult? Patient/Clinical information communicated? Patient/clinical information communicated?
Ancillary Consults	
] Consult to case management	Consult Reason:
] Consult to social work	Reason for Consult:
] PT eval and treat	Special Instructions:
	Weight Bearing Status:
] Consult PT wound care	Special Instructions:
1 OT avail and treat	Location of Wound?
] OT eval and treat	Special Instructions: Weight Bearing Status:
] Consult to Nutrition	Reason For Consult?
] Consult to Natifical	Purpose/Topic:
1 Consult to Spiritual Care	Reason for consult?
[] Consult to Speech Langauge Pathology	Routine, Once
	Reason for consult:
[] Consult to Wound Ostomy Care Nurse	Reason for consult:
	Reason for consult:
	Reason for consult:
	Reason for consult: Consult for NPWT:
	Reason for consult:
Consult transplant social work	Reason for Consult?
[] Consult transplant social work	Organ Transplant: